Biologics
Contributor since: 2018
Articles
Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Semler Scientific: Growth, Profits, And Valuation Models Support A Buy
Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
Clovis Oncology: Managing A Winning Position After Recent Company Updates
Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Marketplace Roundtable - Part 6 - Biotech And Healthcare
Affimed: Preparing For Key Inflection Points
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Genmab: Looking For Growth At A Reasonable Price
ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission
Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
Aquestive Therapeutics: Sell-Off Prompts A Change In Tactics
MultiPlan Corporation: Adding This Growing Healthcare Tech Play To The 'Bio Boom' Portfolio
Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
Halozyme: Antares Pharma Bolsters Growth Prospects
Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation
Esperion Therapeutics: 2021 Labors Paying Off In 2022
Mustang Bio: The Market Is Missing This Opportunity
Eli Lilly's Q1 Earnings Beat Makes It A Safe Haven In A Volatile Market
Healthy Dividends: Organic Growth Points North For West Pharmaceutical Services
Amarin Corp.: Hitting The Thesis Reset Button
Verastem: Time To Take My Position Out Of Mothball
Bicycle Therapeutics: Trying To Catch This Falling Knife
Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope
Affimed Stock: 3 Points For The Bulls
Lantheus: Managing A Winner
Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Clovis Oncology: Forging A Fresh Perspective
CytoDyn: Holding Onto The Ruins From An End Of An Era
Schrödinger: Holding The Keys To Discovery
Healthy Dividends: Bullish On Medtronic's Dividend Aristocrat Status
Healthy Dividends: Amgen's Growth Makes It A 'Top Idea' And Reinforces Its Position In My Dividend Portfolio
TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business
Global Blood Therapeutics: Changing My Strategy After Recent Earnings
AVEO Pharmaceuticals: Finally Ready To Reboot
Puma Bio: Still Worthy Of Consideration After Earnings Surprise
Evolent Health: Finding Steady Growth At An Acceptable Valuation